Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Reardon

Showing results (51-60 of 404) with videos related to

Pageof 41
Sort By:
Current Opinion in Neurology|April 4, 2017
Immunomodulation for glioblastomaDavid A Reardon, Patrick Y Wen, Kai W Wucherpfennig, et al.
Current Treatment Options in Neurology|March 10, 2015
How treatment monitoring is influencing treatment decisions in glioblastomasMartha R Neagu, Raymond Y Huang, David A Reardon, et al.
Nature Medicine|August 8, 2018
Immunotherapy for glioblastoma: going viralJ Bryan Iorgulescu, David A Reardon, E Antonio Chiocca, et al.
Discovery Medicine|July 16, 2015
One size should not fit all: advancing toward personalized glioblastoma therapyDavid A Reardon, Keith L Ligon, E Antonio Chiocca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2006
Recent advances in the treatment of malignant astrocytomaDavid A Reardon, Jeremy N Rich, Henry S Friedman, et al.
Expert Review of Neurotherapeutics|April 3, 2013
Current and future directions for Phase II trials in high-grade gliomaBrian M Alexander, Eudocia Q Lee, David A Reardon, et al.
Frontiers in Neurology|March 11, 2015
Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining responseRaymond Y Huang, Martha R Neagu, David A Reardon, et al.
Nature Reviews. Neurology|August 12, 2015
Prospects of immune checkpoint modulators in the treatment of glioblastomaMatthias Preusser, Michael Lim, David A Hafler, et al.
Expert Opinion on Drug Discovery|June 2, 2012
Advances in malignant glioma drug discoveryDavid A Reardon, James R Perry, Alba A Brandes, et al.
Journal of Neuro-Oncology|August 25, 2012
A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomasPhioanh Leia Nghiemphu, Albert Lai, Richard M Green, et al.
Pageof 41

Showing results (51-60 of 404) with videos related to

Sort By:
Pageof 41
Current Opinion in Neurology|April 4, 2017
Immunomodulation for glioblastomaDavid A Reardon, Patrick Y Wen, Kai W Wucherpfennig, et al.
Current Treatment Options in Neurology|March 10, 2015
How treatment monitoring is influencing treatment decisions in glioblastomasMartha R Neagu, Raymond Y Huang, David A Reardon, et al.
Nature Medicine|August 8, 2018
Immunotherapy for glioblastoma: going viralJ Bryan Iorgulescu, David A Reardon, E Antonio Chiocca, et al.
Discovery Medicine|July 16, 2015
One size should not fit all: advancing toward personalized glioblastoma therapyDavid A Reardon, Keith L Ligon, E Antonio Chiocca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2006
Recent advances in the treatment of malignant astrocytomaDavid A Reardon, Jeremy N Rich, Henry S Friedman, et al.
Expert Review of Neurotherapeutics|April 3, 2013
Current and future directions for Phase II trials in high-grade gliomaBrian M Alexander, Eudocia Q Lee, David A Reardon, et al.
Frontiers in Neurology|March 11, 2015
Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining responseRaymond Y Huang, Martha R Neagu, David A Reardon, et al.
Nature Reviews. Neurology|August 12, 2015
Prospects of immune checkpoint modulators in the treatment of glioblastomaMatthias Preusser, Michael Lim, David A Hafler, et al.
Expert Opinion on Drug Discovery|June 2, 2012
Advances in malignant glioma drug discoveryDavid A Reardon, James R Perry, Alba A Brandes, et al.
Journal of Neuro-Oncology|August 25, 2012
A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomasPhioanh Leia Nghiemphu, Albert Lai, Richard M Green, et al.
Pageof 41